Tuberculosis remains one of the most consequential infectious disease failures of the modern era — not because effective treatments don't exist, but because the gap between what's possible and what's being achieved keeps widening in specific populations and geographies. With global health funding now under fresh strain, understanding exactly where TB control has succeeded or stagnated between 1990 and 2023 becomes foundational for any credible response strategy.
This Global Burden of Disease 2023 analysis — spanning 204 countries and territories — quantifies TB mortality, morbidity, and disability-adjusted life-years with exceptional granularity, stratifying outcomes by HIV co-infection status and multidrug-resistant TB (MDR-TB) separately. Researchers employed the Cause of Death Ensemble model alongside DisMod-MR 2.1 to simultaneously estimate incidence, prevalence, and mortality by age and sex. A population attributable fraction framework was applied to isolate the contributions of alcohol use, smoking, and elevated fasting plasma glucose to overall TB burden — a methodological step that moves this analysis beyond simple epidemiological accounting into actionable risk attribution. The WHO End TB Strategy targets a 95% reduction in TB deaths and a 90% reduction in incidence between 2015 and 2035, benchmarks against which each country's trajectory is assessed.
For researchers and public health professionals, the MDR-TB stratification is arguably the most clinically consequential element. Drug-resistant TB has historically been undercounted in burden estimates, and linking these figures to HIV status adds another dimension that complicates treatment pathway planning. The inclusion of modifiable metabolic and behavioral risk factors — particularly hyperglycemia, which amplifies TB susceptibility through immune suppression — signals a maturing of TB epidemiology toward integrated noncommunicable disease thinking. A key limitation is that data quality varies enormously across the 204 territories, with vital registration coverage weakest precisely where TB burden is highest. This is a systematic analysis, not a randomized trial, so causal inference remains constrained. Still, as a comprehensive pre-disruption baseline at a moment when funding contractions threaten surveillance infrastructure itself, this GBD installment carries unusual strategic weight.